KC eye doc: New LASIK procedure could grow patient base
Dr. John Doane said a growing number of patients are coming to his office for a new surgical alternative to LASIK.
Recently approved by the Food and Drug Administration (FDA) to treat nearsighted patients, small incision lenticule extraction (SMILE) makes a tiny incision in the outer cornea, for a shorter recovery time and fewer dry-eye side effects.
Doane participated in a clinical trial starting in 2013 and expects it will be approved to treat astigmatism in mid-2018. An opthalmologist at Discover… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 15, 2017 Category: Pharmaceuticals Authors: Elise Reuter Source Type: news
Bausch and Lomb ULTRA(R) for Astigmatism Contact Lenses Introduced
Innovative Toric Lens Delivers All-Day Comfort and Consistently Clear Vision1
LAVAL, Quebec, March 30, 2017 -- (Healthcare Sales & Marketing Network) -- Valeant Pharmaceuticals International, Inc.'s (NYSE: VRX and TSX: VRX) wholly owned subsidiary, Bau... Devices, Ophthalmology, Product Launch Bausch & Lomb, ULTRA for Astigmatism, Astigmatism, contact lens (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 30, 2017 Category: Pharmaceuticals Source Type: news
Bausch and Lomb Introduces Biotrue(R) ONEday For Astigmatism Contact Lenses
New Innovative Daily Disposable Contact Lens Designed to Provide Astigmatic Patients
Consistently Clear Vision and Comfort Throughout the Day
LAVAL, Quebec, March 15, 2017 -- (Healthcare Sales & Marketing Network) -- Valeant Pharmaceuticals Interna... Devices, Ophthalmology, Product Launch Bausch & Lomb, Valeant Pharmaceuticals, Biotrue, Astigmatism, contact lens (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 15, 2017 Category: Pharmaceuticals Source Type: news
FDA Clears New Corrective Intraocular Lens From Alcon FDA Clears New Corrective Intraocular Lens From Alcon
The AcrySof IQ ReSTOR +3.0D Multifocal Toric IOL corrects presbyopia and pre-existing corneal astigmatism at the time of cataract surgery in adults.FDA Approvals (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - February 3, 2017 Category: Opthalmology Tags: Ophthalmology News Alert Source Type: news
MassDevice.com +5 | The top 5 medtech stories for December 27, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. FDA approves Alcon’s AcrySof IQ ReStor intraocular lens
Novartis‘ eye care business, Alcon, said today that it won FDA approval for its AcrySof IQ ReStor multifocal toric intraocular lens. The lens treats presbyopia and pre...
Source: Mass Device - December 27, 2016 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news
FDA approves Alcon ’ s AcrySof IQ ReStor intraocular lens
Novartis‘ (NYSE:NVS) eye care business, Alcon, said today that it won FDA approval for its AcrySof IQ ReStor multifocal toric intraocular lens. The lens treats presbyopia and pre-existing corneal astigmatism in adult patients undergoing cataract surgery.
The AcrySof IQ ReStor intraocular lens is already commercially available in the E.U., Australia, Canada, parts of Central and South America and Asia.
“The AcrySof IQ ReSTOR +3.0D Multifocal Toric IOL is an important addition to our market-leading IOL portfolio, and broadens our offering of presbyopia- and astigmatism-correcting lenses to meet the different visu...
Source: Mass Device - December 23, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Food & Drug Administration (FDA) Optical/Ophthalmic Regulatory/Clearance Wall Street Beat Alcon Novartis AG Source Type: news
Lensar files for Chapter 11 bankruptcy
Lensar Inc. today filed for Chapter 11 bankruptcy protection, saying it needs to reduce its debt and strengthen its balance sheet and platform for future growth.
The Orlando, Fl.-based company was supported by its senior secured lender, PDL BioParhma Inc.
In December 2015, healthcare and social commerce company Alphaeon bought the laser cataract treatment company for $59 million.
Lensar said it anticipates that the company will file a plan to reduce its debt and convert a portion of PDL’s outstanding debt into equity. In the meantime, Lensar will continue to pay all employee wages and provide benefits, as well as p...
Source: Mass Device - December 19, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Legal News Optical/Ophthalmic Wall Street Beat LensAR Inc. Source Type: news
Staar Surgical wins Health Canada nod for Visian Toric ICL
Staar Surgical (NSDQ:STAA) said today it won approval from Health Canada’s Medical Devices Bureau for its Evo Visian Toric ICL intraocular lenses.
The Evo Visian Toric ICL is designed to be implanted inside the eye between the iris and the natural lens indefinitely to correct vision, Monrovia, Calif.-based Staar Surgical said.
“We are very pleased with Health Canada’s approval that allows us to offer the EVO Toric ICL for myopia and astigmatism, with a broad spherical power range of -3.0 to -18.0 diopters and cylinder power range of 1.0 to 6.0 diopters, to our surgeons and their patients in Canada. This repre...
Source: Mass Device - September 22, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Optical/Ophthalmic Regulatory/Compliance STAAR Surgical Co Source Type: news
Staar Surgical inks 44-hospital distribution deal in India
Staar Surgical (NSDQ:STAA) said yesterday it inked a distribution agreement with India-based EyeQ Vision Private to distribute Staar Evo Visian ICL intraocular lenses as a treatment for refractive vision treatment.
The deal includes supplying the lenses to 44 hospitals in north and west India, with plans to increase the number to 70 hospitals, including south and west India, within the next 2 years.
“With expansion plans to grow from our 44 hospitals in North and West India to over 70 hospitals including South and West India within the next two years, we made the decision to partner with STAAR Surgical to offer the...
Source: Mass Device - September 16, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Distribution Optical/Ophthalmic STAAR Surgical Co Source Type: news
'Internal astigmatism' doesn't compensate for changes in the eye over time
(Wolters Kluwer Health) For people with nearsightedness (myopia), the lens doesn't compensate for growth or other changes in the structure of the eye, according to a long-term follow-up study in the September issue of Optometry and Vision Science, official journal of the American Academy of Optometry. The journal is published by Wolters Kluwer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 29, 2016 Category: Global & Universal Source Type: news
A'Symfony' of Hope for Cataract Patients A'Symfony' of Hope for Cataract Patients
From distance and near vision to astigmatism and chromatic aberration, the new Symfony intraocular lens seems to correct it all.Wills Eye Hospital (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - August 12, 2016 Category: Drugs & Pharmacology Tags: Ophthalmology Commentary Source Type: news
MassDevice.com +5 | The top 5 medtech stories for July 18, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. T2 Biosystems, Bayer ink blood disorder deal
T2 Biosystems said today that it inked a deal with Bayer for research on blood coagulation disorders.
The deal calls for T2 to provide its T2MR magnetic resonance-based diagnostic de...
Source: Mass Device - July 18, 2016 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news
FDA approves Abbott’s Tecnis Symfony lens for cataracts
The FDA last week granted pre-market approval to the Tecnis Symfony intraocular lens made by Abbott Medical Optics (NYSE:ABT) for treating patients with cataracts.
The device is the 1st intra-ocular lens to provide extended depth of focus for better vision at near, intermediate and far distances, the federal safety watchdog said. Abbott said the FDA also approved a version for patients with astigmatism called the Tecnis Symfony Toric intraocular lens.
“Abbott is focused on improving people’s vision and their lives by helping them stay healthy and active. Symfony offers patients, including those with astigmatis...
Source: Mass Device - July 18, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Food & Drug Administration (FDA) Optical/Ophthalmic Regulatory/Compliance Abbott Source Type: news
FDA Approves the Tecnis Symfony ® Intraocular Lenses, the First and Only Extended Depth of Focus Lenses for People with Cataracts
- Approval includes Toric version of Symfony IOL for people with astigmatism (Source: Abbott.com)
Source: Abbott.com - July 15, 2016 Category: Pharmaceuticals Source Type: news
FDA Approves the Tecnis Symfony® Intraocular Lenses, the First and Only Extended Depth of Focus Lenses for People with Cataracts
- Approval includes Toric version of Symfony IOL for people with astigmatism (Source: Abbott.com)
Source: Abbott.com - July 15, 2016 Category: Pharmaceuticals Source Type: news
